Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

NCT: NCT07510607 · NOT_YET_RECRUITING

NCT IDNCT07510607
StatusNOT_YET_RECRUITING
Start Date2026-04-01
Completion2029-12-01

Brief Summary

The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression. This method of imaging utilizes the Warburg effect, where innate immune cells utilize a metabolic shift to glycolysis instead of oxidative phosphorylation. In pre-clinical data, increased hyperpolarized lactate production has been found to be associated with increased microglial/macrophage infiltration in the brain. Although hyperpolarized carbon imaging in humans has been established and used in the field of oncology, this will be one of the first applications of hyperpolarized carbon the study of neuroinflammation in humans. We predict that hyperpolarized carbon imaging may have the potential to monitor and evaluate neuroinflammation in MS, and in particular the innate immune activation state that plays a role in MS progression. This imaging method may provide non-invasive monitoring of disease progression and therapy response for MS patients.

Frequently Asked Questions

What is Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis?

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis is a clinical trial registered under NCT07510607. Current status: NOT_YET_RECRUITING.

What is the status of NCT07510607?

The current status of NCT07510607 (Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis) is: NOT_YET_RECRUITING.

When did Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis start?

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis started on 2026-04-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.